COMPANY

Trefoil Therapeutics

HQ: San Diego, CA source · trefoiltherapeutics.com ↗

Keywords: ophthalmology Corneal Endothelial Dystrophy Fuchs' Endothelial Dystrophy Fuchs Dystrophy Fuchs Fuchs Endothelial Corneal Dystrophy Pseudophakic Bullous Keratopathy Endothelial Dysfunction Corneal Epithelial Degeneration TTHX1114(NM141) TTHX1114

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

4Trials (company is sponsor)

Timeline

Dec 6, 2022 Trial start Phase 1: Dose Escalation TTHX1114 Ophthalmic Solution source ↗
Nov 30, 2021 Trial start Phase 2: A Safety and Efficacy Trial of TTHX1114 in People With CED source ↗
Feb 1, 2021 Trial start Phase 2: TTHX1114(NM141) in Combination With DWEK/DSO source ↗
Aug 19, 2020 Trial start 1: A Phase 1/ Phase 2 Study of TTHX1114(NM141) source ↗

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT04676737	TTHX1114(NM141) in Combination With DWEK/DSO	Phase 2	Completed	Feb 1, 2021	Nov 16, 2022 (actual)
NCT04812067	A Safety and Efficacy Trial of TTHX1114 in People With CED	Phase 2	Completed	Nov 30, 2021	Aug 29, 2023 (actual)
NCT04520321	A Phase 1/ Phase 2 Study of TTHX1114(NM141)	1	Completed	Aug 19, 2020	Apr 23, 2021 (actual)
NCT05769920	Dose Escalation TTHX1114 Ophthalmic Solution	Phase 1	Completed	Dec 6, 2022	Apr 12, 2023 (actual)